Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 10/20 | 0.48 |
| ▸ | CDC25B | P30305 | 8/20 | 0.48 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.48 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.48 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 5/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 5/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 4/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | GJB2 | P29033 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26447373 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL2804791 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL10259814 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL6895176 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL14616676 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL19204220 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL6574752 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL13129824 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL15975379 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 | |
| SCHEMBL2287945 | 1.00 | NT5E (0.57) | NT5EPTPN1CDC25BSSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10919941-B2 | Functional lipid constructs | KODE BIOTECH LIMITED (NZ) | 2021-02-16 | — | — | US | disclosed |
| US-10858384-B2 | Synthetic molecule constructs | KODE BIOTECH LIMITED (NZ) | 2020-12-08 | — | — | US | disclosed |
| US-20200123188-A1 | SYNTHETIC MOLECULE CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2020-04-23 | — | — | US | disclosed |
| US-10414786-B2 | Synthetic membrane anchors | KODE BIOTECH LIMITED (NZ) | 2019-09-17 | — | — | US | disclosed |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | KODE BIOTECH LTD. (NZ) | 2018-03-01 | — | — | US | disclosed |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | KODE BIOTECH LIMITED (NZ) | 2017-08-03 | — | — | US | disclosed |
| US-20160361423-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LTD (NZ) | 2016-12-15 | — | — | US | disclosed |
| US-9226968-B2 | Carbohydrate-lipid constructs and their use in preventing or treating viral infection | KODE BIOTECH LIMITED (NZ) | 2016-01-05 | — | — | US | disclosed |
| US-20140200191-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2014-07-17 | — | — | US | disclosed |
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2012-11-01 | — | — | US | disclosed |
| US-8211860-B2 | Carbohydrate-lipid constructs and their use in preventing or treating viral infection | KODE BIOTECH LIMITED (NZ) | 2012-07-03 | — | — | US | disclosed |
| US-20100184723-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | KODE BIOTECH LIMITED (NZ) | 2010-07-22 | — | — | US | disclosed |
| EP-0970114-B1 | NEOGLYCOPROTEINS | NOVARTIS AG (CH) | 2006-07-12 | — | — | EP | disclosed |
| US-6723831-B2 | REMOVAL ANTIBODIES FROM BODY FLUIDS | NOVARTIS AG (CH) | 2004-04-20 | — | — | US | disclosed |
| US-6399071-B1 | Neoglycoproteins | NOVARTIS AG (CH) | 2002-06-04 | — | — | US | disclosed |
| EP-0970114-A1 | NEOGLYCOPROTEINS | Novartis AG (CH) | 2000-01-12 | — | — | EP | disclosed |
| WO-1998047915-A1 | NEOGLYCOPROTEINS | NOVARTIS AG (CH) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140200191-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | NT5E 1700/4885PTPN1 967/4885CDC25B 3462/4885 |
| US-20160361423-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | NT5E 1700/4885PTPN1 967/4885CDC25B 3462/4885 |
| US-20170218027-A1 | FUNCTIONAL LIPID CONSTRUCTS | CETP, LCAT, LIPA | NT5E 2160/4885PTPN1 2488/4885CDC25B 4058/4885 |
| US-10919941-B2 | Functional lipid constructs | CETP, LCAT, LIPA | NT5E 2160/4885PTPN1 2488/4885CDC25B 4058/4885 |
| US-20180057518-A1 | SYNTHETIC MEMBRANE ANCHORS | PTDSS2, DDOST, STT3B | NT5E 2691/4885PTPN1 4708/4885CDC25B 1049/4885 |
| US-20100184723-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, CD14 | NT5E 1558/4885PTPN1 949/4885CDC25B 3384/4885 |
| US-20200123188-A1 | SYNTHETIC MOLECULE CONSTRUCTS | PTDSS2, PTDSS1, UGCG | NT5E 1938/4885PTPN1 4188/4885CDC25B 2690/4885 |
| US-20120277172-A1 | CARBOHYDRATE-LIPID CONSTRUCTS AND THEIR USE IN PREVENTING OR TREATING VIRAL INFECTION | HAVCR2, SIGLEC7, FUT5 | NT5E 1700/4885PTPN1 967/4885CDC25B 3462/4885 |
| US-10414786-B2 | Synthetic membrane anchors | PTDSS2, DDOST, STT3B | NT5E 2634/4885PTPN1 4704/4885CDC25B 1118/4885 |
| US-10858384-B2 | Synthetic molecule constructs | PTDSS2, PTDSS1, UGCG | NT5E 1942/4885PTPN1 4189/4885CDC25B 2653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.